De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca

Inclusion Criteria

• •1. ≥ 18 years of age
• •2. T0-3, N0 to N2c, M0 squamous cell carcinoma of the oropharynx
• •3. Biopsy proven squamous cell carcinoma that is HPV and/or p16 positive
• •4. ≤ 10 pack-years smoking history or \> 5 years of abstinence from smoking
• •5. History/physical examination within 8 weeks prior to registration
• •6. Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration.
• •7. The Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
• •8. Complete Blood Count (CBC)/differential obtained within 4 weeks prior to registration, with adequate bone marrow function defined as follows: Absolute neutrophil count (ANC) ≥ 1,800 cells/mm3; Platelets ≥ 100,000 cells/mm3; Hemoglobin ≥ 8.0 g/dl.
• •9. Adequate renal and hepatic function within 4 weeks prior to registration, defined as follows: Serum creatinine \< 2.0 mg/dl; Total bilirubin \< 2 x the institutional upper limit of normal (ULN); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \< 3 x the institutional ULN.
• •10. Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential.
• •11. Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatment.
• •12. Patients must be deemed able to comply with the treatment plan and follow-up schedule.
• •13. Patients must provide study specific informed consent prior to study entry.